WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H406234
CAS#: 295337-71-2
Description: BMS-317180 is a potent, novel, orally effective growth hormone secretagogue (GHS) that shows an excellent safety profile in preclinical studies. The compound was advanced into clinical development.
Hodoodo Cat#: H406234
Name: BMS-317180
CAS#: 295337-71-2
Chemical Formula: C21H33N7O5
Exact Mass: 463.25
Molecular Weight: 463.530
Elemental Analysis: C, 54.41; H, 7.18; N, 21.15; O, 17.26
Synonym: BMS317180; BMS-317180; BMS 317180.
IUPAC/Chemical Name: (S)-2-(5-(1-(2-amino-2-methylpropanamido)-2-(benzyloxy)ethyl)-1H-tetrazol-1-yl)ethyl (4-hydroxybutyl)carbamate
InChi Key: KJXOYJXMFGXDRR-QGZVFWFLSA-N
InChi Code: InChI=1S/C21H33N7O5/c1-21(2,22)19(30)24-17(15-32-14-16-8-4-3-5-9-16)18-25-26-27-28(18)11-13-33-20(31)23-10-6-7-12-29/h3-5,8-9,17,29H,6-7,10-15,22H2,1-2H3,(H,23,31)(H,24,30)/t17-/m1/s1
SMILES Code: O=C(OCCN1N=NN=C1[C@H](NC(C(C)(N)C)=O)COCC2=CC=CC=C2)NCCCCO
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 463.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Davulcu AH, McLeod DD, Li J, Katipally K, Littke A, Doubleday W, Xu Z, McConlogue CW, Lai CJ, Gleeson M, Schwinden M, Parsons RL Jr. Process research and development for a tetrazole-based growth hormone secretagogue (GHS) pharmaceutical development candidate. J Org Chem. 2009 Jun 5;74(11):4068-79. doi: 10.1021/jo9003508. PubMed PMID: 19391593.
2: Li J, Chen SY, Murphy BJ, Flynn N, Seethala R, Slusarchyk D, Yan M, Sleph P, Zhang H, Humphreys WG, Ewing WR, Robl JA, Gordon D, Tino JA. (D)-2-tert-Butoxycarbonylamino-5,5-difluoro-5-phenyl-pentanoic acid: synthesis and incorporation into the growth hormone secretagogues. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4072-4. doi: 10.1016/j.bmcl.2008.05.100. Epub 2008 Jun 12. PubMed PMID: 18554903.
3: Li J, Chen SY, Tao S, Wang H, Li JJ, Swartz S, Musial C, Hernandez AA, Flynn N, Murphy BJ, Beehler B, Dickinson KE, Giupponi L, Grover G, Seethala R, Sleph P, Slusarchyk D, Yan M, Humphreys WG, Zhang H, Ewing WR, Robl JA, Gordon D, Tino JA. Design and synthesis of tetrazole-based growth hormone secretagogue: the SAR studies of the O-benzyl serine side chain. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1825-9. doi: 10.1016/j.bmcl.2008.02.021. Epub 2008 Feb 13. PubMed PMID: 18295486.
4: Li J, Chen SY, Li JJ, Wang H, Hernandez AS, Tao S, Musial CM, Qu F, Swartz S, Chao ST, Flynn N, Murphy BJ, Slusarchyk DA, Seethala R, Yan M, Sleph P, Grover G, Smith MA, Beehler B, Giupponi L, Dickinson KE, Zhang H, Humphreys WG, Patel BP, Schwinden M, Stouch T, Cheng PT, Biller SA, Ewing WR, Gordon D, Robl JA, Tino JA. Discovery of a tetrazole-based growth hormone secretagogue: 4-(hydroxybutyl)carbamic acid 2-{5-[1-(2-amino-2-methylpropionylamino)-2- benzyloxyethyl]tetrazol-1-yl}ethyl ester (BMS-317180). J Med Chem. 2007 Nov 29;50(24):5890-3. Epub 2007 Oct 31. PubMed PMID: 17973363.